購読する
モデル製品
サービス
前臨床薬効評価
コミュ二ティー
B6-hB2M&HLA-A2.1/mB2m KO Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
B6-hB2M&HLA-A2.1/mB2m KO Mouse
製品名
B6-hB2M&HLA-A2.1/mB2m KO Mouse
製品ID
C001696
系統名
C57BL/6N;6JCya-Igs2em1(B2M/HLA-A2.1/H2-D1)B2mem2/Cya
背景情報
C57BL/6N;6JCya
状況
このマウス系統を論文で使用する場合は、「B6-hB2M&HLA-A2.1/mB2m KO Mouse(カタログ番号C001696)はサイアジェンから購入しました。」と引用してください。
Other Target Humanized Mouse Models
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
Other Target Humanized Mouse Models
基本情報
関連リソース
基本情報
遺伝子別名
Ly-m11, beta2m, beta2-m, HLAA, IMD43
染色体
Chr 2, Chr 6, Chr 15
MGI ID
さらに
系統詳細
The B2M gene encodes beta-2 microglobulin, a serum protein on the surface of nearly all nucleated cells along with the major histocompatibility complex (MHC) class I heavy chain. It is an essential component for transporting MHC class I proteins to the cell surface. Human leukocyte antigen (HLA), or the major histocompatibility complex (MHC), is a group of protein molecules on the surface of antigen-presenting cells responsible for antigen presentation. HLA mainly includes HLA class I, HLA class II, and HLA class III. HLA class I molecules (such as HLA-A, HLA-B, and HLA-C) primarily present antigens to CD8+ T cells and play a central role in the immune system. Through antigen presentation by HLA class I, the body can effectively recognize abnormal peptides, triggering targeted immune responses for immune clearance. Studies have shown that peptide vaccines composed of covalently linked minimal cytotoxic T lymphocyte (CTL) and T helper cell (TH) epitopes have significant effects in inducing cellular immune responses [1]. Due to species differences between mice and humans, and the varying ability of different HLA molecule subtypes to present different antigens, mouse-derived HLA cannot effectively simulate the immune response of human HLA subtypes. Therefore, constructing mice carrying human HLA genes helps to advance the study of HLA-restricted cytotoxic responses, such as identifying immunodominant HLA-restricted CTL epitopes and optimizing DNA vaccine constructs for human use [2-3].
HLA-A2.1 is a subtype of class I HLA and is one of the most common HLA subtypes worldwide. HLA-A2.1 plays an important role in the immune system, especially in the presentation of antigens such as viruses, bacteria, and parasites to cytotoxic T cells (CD8+ T cells). This presentation process is essential for the immune response of the human body to a variety of pathogens, particularly in the response to human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). In addition, HLA-A2.1 is also involved in the immune response to cancer cells, further emphasizing its importance in the human immune system.
The B6-hB2M&HLA-A2.1/mB2m KO mice are a humanized model obtained by mating H11-hB2M&HLA-A2.1 mice (Catalog Number: I001138) with B2m gene knockout mouse model (Catalog Number: S-KO-19919). While knocking out the mouse B2m gene, the chimeric H2-K1 HLA-A2.1 gene is integrated into the H11 safe harbor locus, which may be able to recapitulate the immune response of the human HLA-A*0201 (MHCI) subtype. This model can play an important role in studying the determinants of HLA-A2.1-restricted cytotoxic T lymphocytes (CTLs) and the development of potential viral vaccines and helps research the human immune response to a variety of antigens.
参考文献
La Rosa C, Wang Z, Brewer JC, Lacey SF, Villacres MC, Sharan R, Krishnan R, Crooks M, Markel S, Maas R, Diamond DJ. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood. 2002 Nov 15;100(10):3681-9.
Gotoh M, Takasu H, Harada K, Yamaoka T. Development of HLA-A2402/K(b) transgenic mice. Int J Cancer. 2002 Aug 10;100(5):565-70.
Boucherma R, Kridane-Miledi H, Bouziat R, Rasmussen M, Gatard T, Langa-Vives F, Lemercier B, Lim A, Bérard M, Benmohamed L, Buus S, Rooke R, Lemonnier FA. HLA-A*01:03, HLA-A*24:02, HLA-B*08:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 monochain transgenic/H-2 class I null mice: novel versatile preclinical models of human T cell responses. J Immunol. 2013 Jul 15;191(2):583-93.
系統作製戦略

Figure 1. Strategy for generating H11-hB2M&HLA-A2.1 mice.
A synthetic gene expression cassette—“Mouse K2-K1 promoter–Kozak–HLA-A2.1 leader sequence–Human Mature B2M CDS–3×GGGGS linker–Chimeric HLA-A2.1 (HLA-A2.1 α1 and α2 binding domains fused to H2-D1 α3, cytoplasmic, and transmembrane domains)–H2-D1 3′ sequence”—was integrated into the murine H11 safe harbor locus using genome editing technologies.
A synthetic gene expression cassette—“Mouse K2-K1 promoter–Kozak–HLA-A2.1 leader sequence–Human Mature B2M CDS–3×GGGGS linker–Chimeric HLA-A2.1 (HLA-A2.1 α1 and α2 binding domains fused to H2-D1 α3, cytoplasmic, and transmembrane domains)–H2-D1 3′ sequence”—was integrated into the murine H11 safe harbor locus using genome editing technologies.

Figure 2. Gene editing strategy for mB2m KO mice.
Exons 2 to 3 of the endogenous mouse B2m gene were knocked out.
Exons 2 to 3 of the endogenous mouse B2m gene were knocked out.
適用分野
Development and testing of novel viral vaccines;
Testing of drug and vaccine safety and immunogenicity;
Research on oncology and autoimmune diseases;
Research on the interaction mechanism between human immune cells and pathogens;Research on allogeneic tumor transplantation
関連リソース
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
